Gilles N. Stormezand MD, PhD , Eline de Meyer PhD , Klaas Pieter Koopmans PhD , Adrienne H. Brouwers PhD , G. Luurtsema PhD , Rudi A.J.O. Dierckx MD, PhD
{"title":"关于[18F]FDOPA PET/CT 作用的最新进展。","authors":"Gilles N. Stormezand MD, PhD , Eline de Meyer PhD , Klaas Pieter Koopmans PhD , Adrienne H. Brouwers PhD , G. Luurtsema PhD , Rudi A.J.O. Dierckx MD, PhD","doi":"10.1053/j.semnuclmed.2024.09.004","DOIUrl":null,"url":null,"abstract":"<div><div>[<sup>18</sup>F]-dihydroxyphenylalanine ([<sup>18</sup>F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [<sup>18</sup>F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [<sup>18</sup>F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease. New developments as the advent of large axial field of view PET/CT or integrated PET/MRI systems may provide more unique opportunities, such as those related to detection of smaller lesions in primary staging of NETs, dose reduction in children with congenital hyperinsulinism, or possibilities to obtain more extensive noninvasive quantification of cerebral uptake by using image derived input functions. Although the widespread use of [<sup>18</sup>F]FDOPA has been hampered by complex synthesis methods and high production costs in the past, significant efforts have been undertaken to provide robust GMP compliant synthesis methods with high activity yield and molar activity.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 6","pages":"Pages 845-855"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Update on the Role of [18F]FDOPA PET/CT\",\"authors\":\"Gilles N. Stormezand MD, PhD , Eline de Meyer PhD , Klaas Pieter Koopmans PhD , Adrienne H. Brouwers PhD , G. Luurtsema PhD , Rudi A.J.O. Dierckx MD, PhD\",\"doi\":\"10.1053/j.semnuclmed.2024.09.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>[<sup>18</sup>F]-dihydroxyphenylalanine ([<sup>18</sup>F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [<sup>18</sup>F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [<sup>18</sup>F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease. New developments as the advent of large axial field of view PET/CT or integrated PET/MRI systems may provide more unique opportunities, such as those related to detection of smaller lesions in primary staging of NETs, dose reduction in children with congenital hyperinsulinism, or possibilities to obtain more extensive noninvasive quantification of cerebral uptake by using image derived input functions. Although the widespread use of [<sup>18</sup>F]FDOPA has been hampered by complex synthesis methods and high production costs in the past, significant efforts have been undertaken to provide robust GMP compliant synthesis methods with high activity yield and molar activity.</div></div>\",\"PeriodicalId\":21643,\"journal\":{\"name\":\"Seminars in nuclear medicine\",\"volume\":\"54 6\",\"pages\":\"Pages 845-855\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001299824000801\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000801","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
[18F]-二羟基苯丙氨酸([18F]FDOPA)是一种放射性药物,可用于多种疾病,包括神经内分泌肿瘤(NET)、先天性高胰岛素血症、帕金森综合征和神经肿瘤。基因分析和疾病特异性生物标志物可指导在几种神经内分泌肿瘤和先天性高胰岛素血症的不同阶段对可能从[18F]FDOPA PET中获益最多的患者进行最佳选择。在神经肿瘤学的临床常规治疗中,[18F]FDOPA PET 的适应症包括肿瘤分界以及区分治疗相关变化和复发疾病。随着大轴向视野 PET/CT 或 PET/MRI 集成系统的出现,新的发展可能会提供更多独特的机会,如在 NET 的原发分期中检测较小的病灶、减少先天性高胰岛素血症儿童的剂量,或通过使用图像衍生输入函数获得更广泛的无创量化脑摄取的可能性。虽然[18F]FDOPA 的广泛应用过去一直受到复杂合成方法和高生产成本的阻碍,但现在人们已经做出了巨大努力,以提供具有高活性产率和摩尔活性的符合 GMP 标准的可靠合成方法。
[18F]-dihydroxyphenylalanine ([18F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [18F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [18F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease. New developments as the advent of large axial field of view PET/CT or integrated PET/MRI systems may provide more unique opportunities, such as those related to detection of smaller lesions in primary staging of NETs, dose reduction in children with congenital hyperinsulinism, or possibilities to obtain more extensive noninvasive quantification of cerebral uptake by using image derived input functions. Although the widespread use of [18F]FDOPA has been hampered by complex synthesis methods and high production costs in the past, significant efforts have been undertaken to provide robust GMP compliant synthesis methods with high activity yield and molar activity.
期刊介绍:
Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.